GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
  • 1
    In: Diabetes Care, American Diabetes Association, Vol. 43, No. 4 ( 2020-04-01), p. 806-812
    Abstract: To evaluate the contemporary prevalence of diabetic peripheral neuropathy (DPN) in participants with type 1 diabetes in the T1D Exchange Clinic Registry throughout the U.S. RESEARCH DESIGN AND METHODS DPN was assessed with the Michigan Neuropathy Screening Instrument Questionnaire (MNSIQ) in adults with ≥5 years of type 1 diabetes duration. A score of ≥4 defined DPN. Associations of demographic, clinical, and laboratory factors with DPN were assessed. RESULTS Among 5,936 T1D Exchange participants (mean ± SD age 39 ± 18 years, median type 1 diabetes duration 18 years [interquartile range 11, 31], 55% female, 88% non-Hispanic white, mean glycated hemoglobin [HbA1c] 8.1 ± 1.6% [65.3 ± 17.5 mmol/mol]), DPN prevalence was 11%. Compared with those without DPN, DPN participants were older, had higher HbA1c, had longer duration of diabetes, were more likely to be female, and were less likely to have a college education and private insurance (all P & lt; 0.001). DPN participants also were more likely to have cardiovascular disease (CVD) (P & lt; 0.001), worse CVD risk factors of smoking (P = 0.008), hypertriglyceridemia (P = 0.002), higher BMI (P = 0.009), retinopathy (P = 0.004), reduced estimated glomerular filtration rate (P = 0.02), and Charcot neuroarthropathy (P = 0.002). There were no differences in insulin pump or continuous glucose monitor use, although DPN participants were more likely to have had severe hypoglycemia (P = 0.04) and/or diabetic ketoacidosis (P & lt; 0.001) in the past 3 months. CONCLUSIONS The prevalence of DPN in this national cohort with type 1 diabetes is lower than in prior published reports but is reflective of current clinical care practices. These data also highlight that nonglycemic risk factors, such as CVD risk factors, severe hypoglycemia, diabetic ketoacidosis, and lower socioeconomic status, may also play a role in DPN development.
    Type of Medium: Online Resource
    ISSN: 0149-5992 , 1935-5548
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2020
    detail.hit.zdb_id: 1490520-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Diabetes Care, American Diabetes Association, Vol. 43, No. 1 ( 2020-01-01), p. e1-e2
    Type of Medium: Online Resource
    ISSN: 0149-5992 , 1935-5548
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2020
    detail.hit.zdb_id: 1490520-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  Journal of Clinical Oncology Vol. 40, No. 6_suppl ( 2022-02-20), p. 71-71
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 6_suppl ( 2022-02-20), p. 71-71
    Abstract: 71 Background: In oncology practice, there are increasing numbers of patients for whom genetic testing is recommended by the National Cancer Care Network (NCCN), including all metastatic and high-risk localized prostate cancer patients. However, there is a critical shortage of genetics services providers. Acuity for these consults can be high, particularly in the context of a treatment related decision. We hypothesized that nurses, particularly advanced practice nurses (APNs), can provide a workforce within VA that can address genetic testing and genetic care needs of prostate cancer patients. Methods: We initiated a cancer genetics service staffed with an advanced practice nurse (APN) geneticist and evaluated the success of the program at a large urban, academic-affiliated Veteran’s Affairs Medical Center (VAMC). Results: In the one year prior to the initiation of the APN geneticist-run program (10/1/2019-9/30/2020), 61 unaffected patients with a family history of cancer and 85 patients with cancer (36 with prostate cancer) were referred to a VA centralized telegenetics service. An average of seven cancer patients (average three with prostate cancer) were referred to VA telegenetics per month. Genetic testing was completed in eleven (18%) of unaffected patients and 21 (25%) of cancer patients. Five (13%) of tested patients were found to have a pathogenic or likely pathogenic mutation or variant of uncertain significance (VUS). In the eight months after initiation of the APN geneticist-run consult service (10/1/2020 - 5/30/2021), 39 unaffected patients with a family history of cancer and 90 patients with cancer (38 with prostate cancer) were referred. An average of 11 cancer patients (average five with prostate cancer) per month were referred. This represents a 57% increase in all cancer patient and a 67% increase in prostate cancer patient referrals. For those patients referred to the APN geneticist-run consult service, genetic testing was completed in three (7%) of unaffected patients and 30 (33%) of cancer patients (including 15 prostate cancer patients). The genetic testing rate therefore improved from 1.7 oncology patients per month to 3.9 oncology patients per month, an 130% increase in genetic testing. For prostate cancer patients, the genetic testing rate improved from 0.8 to 1.9 patients tested per month, representing a 137% increase. Comparison of genetic testing outcomes at one year will be included in the final presentation. Conclusions: Inclusion of an APN geneticist-run consult service embedded in oncology clinics will likely improve access to genetics services and genetic testing rates in cancer patients.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Environmental Science & Technology, American Chemical Society (ACS), Vol. 54, No. 23 ( 2020-12-01), p. 15296-15312
    Type of Medium: Online Resource
    ISSN: 0013-936X , 1520-5851
    RVK:
    Language: English
    Publisher: American Chemical Society (ACS)
    Publication Date: 2020
    detail.hit.zdb_id: 280653-8
    detail.hit.zdb_id: 1465132-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Chemical Society (ACS) ; 2023
    In:  The Journal of Physical Chemistry C Vol. 127, No. 2 ( 2023-01-19), p. 894-906
    In: The Journal of Physical Chemistry C, American Chemical Society (ACS), Vol. 127, No. 2 ( 2023-01-19), p. 894-906
    Type of Medium: Online Resource
    ISSN: 1932-7447 , 1932-7455
    RVK:
    Language: English
    Publisher: American Chemical Society (ACS)
    Publication Date: 2023
    detail.hit.zdb_id: 2256522-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: ECS Meeting Abstracts, The Electrochemical Society, Vol. MA2022-02, No. 44 ( 2022-10-09), p. 1644-1644
    Abstract: Proton exchange membrane water electrolysis (PEMWE) offers a promising route for the production of green hydrogen from renewable energy sources and could be the master key to unlocking a future sustainable energy system (1). One of the main barriers delaying the wide-spread adoption of PEMWE technologies is the slow kinetics of the oxygen evolution reaction (OER) occurring at the anode and the need for high-cost, low-abundance precious metal electrocatalysts. Iridium-based oxides are still considered the only feasible option for practical applications due to their high activity and considerable corrosion stability under the harsh electrochemical reaction conditions. To improve the overall efficiency of PEMWEs, future electrocatalyst development strategies must concomitantly address performance metrics in terms of activity, stability and material cost. Towards enhancing iridium utilisation, efforts are aimed at increasing the electrochemical surface area of the catalyst per mass of iridium, thereby increasing the number of available electrocatalytic surface sites. In this regard, amorphous iridium oxide (IrO x ) nanoparticles have been shown to achieve a high intrinsic activity (2). However, this comes at the expense of catalyst stability (3) and a loss of intrinsic electronic conductivity (4) associated with the lower degree of crystallinity. By maximising the dispersion of Ir-based nanoparticles, the use of high surface area support materials have also been shown to improve OER performance (5, 6). However, to address long-term stability concerns for Ir-based OER catalysts, highly crystalline rutile iridium dioxide (IrO 2 ) materials may still offer the best prospects. The drawback of using this approach is that the formation of crystalline IrO 2 nanoparticles often involves high temperature thermal oxidative treatment causing particle growth and loss of surface area, ultimately leading to decreased OER activities (7). Therefore, novel synthesis methods that retain a high degree of crystallinity without a loss of surface area for IrO 2 nanoparticles are required. In this talk, we discuss two synthesis strategies geared towards the preparation of highly crystalline IrO 2 nanoparticles with high OER performance. Firstly, we present a novel wet-chemistry synthesis method that avoids the use of reducing agents and eliminates the need for high temperature thermal oxidative treatment. The resultant nano-sized IrO 2 nanoparticles were found to have excellent Ir mass-specific OER activity and durability attributed to the small nanoparticle size and high degree of crystallinity. Secondly, we present a novel metalorganic chemical deposition process as a simple, one-step preparation method for highly crystalline IrO 2 nanoparticles supported on Sb-doped tin oxide (ATO) (8). The superior OER performance was attributed to the epitaxial anchoring of well dispersed, crystalline IrO 2 nanoparticles onto the ATO support. We further discuss the versatility of the method to the application of other conductive oxide support materials such as indium tin oxide and F-doped tin oxide, with the ability of tuning the chemical state of the Ir-based nanoparticles by changing the reaction conditions, i.e., temperature and gas environment as well as the nature of the support. Finally, using a series detailed physico-chemical characterisation techniques to elucidate the nature the iridium phase, composition, morphology and structure, we relate these properties to the electrochemical activity and stability of the prepared materials for the OER. Herein, we highlight some of the challenges often encountered with the analysis of physical and electrochemical characterisation data for IrO 2 nanoparticles, particularly when supported on other oxide materials. Acknowledgements This work is funded by the Department of Science and Innovation (DSI, South Africa) Impala Platinum Holdings Limited (Implats) and the Federal Minister of Education and Research (BMBF, Germany). References K. Ayers, Current Opinion in Electrochemistry , 18 , 9 (2019). T. Reier, I. Weidinger, P. Hildebrandt, R. Kraehnert and P. Strasser, ECS Transactions , 58 , 39 (2013). T. Binninger, R. Mohamed, K. Waltar, E. Fabbri, P. Levecque, R. Kötz and T. J. Schmidt, Scientific Reports , 5 , 12167 (2015). M. Bernt, C. Schramm, J. Schröter, C. Gebauer, J. Byrknes, C. Eickes and H. A. Gasteiger, Journal of The Electrochemical Society , 168 , 084513 (2021). H.-S. Oh, H. N. Nong, T. Reier, A. Bergmann, M. Gliech, J. Ferreira de Araújo, E. Willinger, R. Schlögl, D. Teschner and P. Strasser, Journal of the American Chemical Society , 138 , 12552 (2016). A. Hartig-Weiss, M. Miller, H. Beyer, A. Schmitt, A. Siebel, A. T. S. Freiberg, H. A. Gasteiger and H. A. El-Sayed, ACS Applied Nano Materials , 3 , 2185 (2020). J. Quinson, Advances in Colloid and Interface Science , 303 , 102643 (2022). Z. S. H. S. Rajan, T. Binninger, P. J. Kooyman, D. Susac and R. Mohamed, Catalysis Science & Technology , 10 , 3938 (2020).
    Type of Medium: Online Resource
    ISSN: 2151-2043
    Language: Unknown
    Publisher: The Electrochemical Society
    Publication Date: 2022
    detail.hit.zdb_id: 2438749-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Environment International, Elsevier BV, Vol. 107 ( 2017-10), p. 235-242
    Type of Medium: Online Resource
    ISSN: 0160-4120
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 554791-X
    detail.hit.zdb_id: 1497569-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Environment International, Elsevier BV, Vol. 107 ( 2017-10), p. 181-189
    Type of Medium: Online Resource
    ISSN: 0160-4120
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 554791-X
    detail.hit.zdb_id: 1497569-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Institute of Electrical and Electronics Engineers (IEEE) ; 2007
    In:  IEEE Transactions on Systems, Man and Cybernetics, Part C (Applications and Reviews) Vol. 37, No. 5 ( 2007-09), p. 779-793
    In: IEEE Transactions on Systems, Man and Cybernetics, Part C (Applications and Reviews), Institute of Electrical and Electronics Engineers (IEEE), Vol. 37, No. 5 ( 2007-09), p. 779-793
    Type of Medium: Online Resource
    ISSN: 1094-6977
    Language: Unknown
    Publisher: Institute of Electrical and Electronics Engineers (IEEE)
    Publication Date: 2007
    detail.hit.zdb_id: 2034757-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: JMIR Formative Research, JMIR Publications Inc., Vol. 5, No. 7 ( 2021-7-16), p. e27484-
    Abstract: In cancers with a chronic phase, patients and family caregivers face difficult decisions such as whether to start a novel therapy, whether to enroll in a clinical trial, and when to stop treatment. These decisions are complex, require an understanding of uncertainty, and necessitate the consideration of patients’ informed preferences. For some cancers, such as medullary thyroid carcinoma, these decisions may also involve significant out-of-pocket costs and effects on family members. Providers have expressed a need for web-based interventions that can be delivered between consultations to provide education and prepare patients and families to discuss these decisions. To ensure that these tools are effective, usable, and understandable, studies are needed to identify patients’, families’, and providers’ decision-making needs and optimal design strategies for a web-based patient decision aid. Objective Following the international guidelines for the development of a web-based patient decision aid, the objectives of this study are to engage potential users to guide development; review the existing literature and available tools; assess users’ decision-making experiences, needs, and design recommendations; and identify shared decision-making approaches to address each need. Methods This study used the decisional needs assessment approach, which included creating a stakeholder advisory panel, mapping decision pathways, conducting an environmental scan of existing materials, and administering a decisional needs assessment questionnaire. Thematic analyses identified current decision-making pathways, unmet decision-making needs, and decision support strategies for meeting each need. Results The stakeholders reported wide heterogeneity in decision timing and pathways. Relevant existing materials included 2 systematic reviews, 9 additional papers, and multiple educational websites, but none of these met the criteria for a patient decision aid. Patients and family members (n=54) emphasized the need for plain language (46/54, 85%), shared decision making (45/54, 83%), and help with family discussions (39/54, 72%). Additional needs included information about uncertainty, lived experience, and costs. Providers (n=10) reported needing interventions that address misinformation (9/10, 90%), foster realistic expectations (9/10, 90%), and address mistrust in clinical trials (5/10, 50%). Additional needs included provider tools that support shared decision making. Both groups recommended designing a web-based patient decision aid that can be tailored to (64/64, 100%) and delivered on a hospital website (53/64, 83%), focuses on quality of life (45/64, 70%), and provides step-by-step guidance (43/64, 67%). The study team identified best practices to meet each need, which are presented in the proposed decision support design guide. Conclusions Patients, families, and providers report multifaceted decision support needs during the chronic phase of cancer. Web-based patient decision aids that provide tailored support over time and explicitly address uncertainty, quality of life, realistic expectations, and effects on families are needed.
    Type of Medium: Online Resource
    ISSN: 2561-326X
    Language: English
    Publisher: JMIR Publications Inc.
    Publication Date: 2021
    detail.hit.zdb_id: 2941716-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...